NASDAQ: BRTXBiorestorative Therapies Inc Stock
$5.35+0.00 (+0%)
Updated Jun 2, 2023
BRTX Price
$5.35
Fair Value Price
$5.81
Market Cap
$20.80M
52 Week Low
$2.46
52 Week High
$6.33
P/E
-1.02x
P/B
1.54x
P/S
93.56x
PEG
N/A
Dividend Yield
N/A
Revenue
$135.10k
Earnings
-$19.36M
Gross Margin
100%
Operating Margin
-14,375.81%
Profit Margin
-14,332.2%
Debt to Equity
0.04
Operating Cash Flow
-$7M
Beta
-0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BRTX Overview
BioRestorative Therapies Inc is a biotechnology company developing therapies using cell and tissue protocols, mostly involving non-embryonic stem cells. The company's Disc/Spine Program includesBRTX-100, a cell therapy candidate formulated from stem cells collected from the patient's bone marrow. Its Metabolic Program is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells. BioRestorative Therapies was founded in 1997 and is headquartered in Melville, New York.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BRTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BRTX ($5.35) is undervalued by 7.97% relative to our estimate of its Fair Value price of $5.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BRTX ($5.35) is not significantly undervalued (7.97%) relative to our estimate of its Fair Value price of $5.81 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BRTX due diligence checks available for Premium users.
Be the first to know about important BRTX news, forecast changes, insider trades & much more!
BRTX News
Valuation
BRTX fair value
Fair Value of BRTX stock based on Discounted Cash Flow (DCF)
Price
$5.35
Fair Value
$5.81
Undervalued by
7.97%
BRTX ($5.35) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BRTX ($5.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BRTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BRTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.02x
Industry
11.51x
Market
52.69x
BRTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.54x
Industry
5.2x
BRTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BRTX's financial health
Profit margin
Revenue
$31.3k
Net Income
-$5.7M
Profit Margin
-18,160.5%
BRTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BRTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.1M
Liabilities
$593.9k
Debt to equity
0.04
BRTX's short-term assets ($12.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BRTX's short-term assets ($12.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BRTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BRTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$2.5M
Financing
$0.0
BRTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BRTX vs Biotech Stocks
Biorestorative Therapies Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.